ERBB2 and breast cancer: The aim of the NeoPower study was to collect and analyze the data of patients with HER2 + early breast cancer (eBC) treated in the neoadjuvant setting with P, H and chemotherapy in different cancer centers in Emilia Romagna, in order to evaluate the tolerability and efficacy of the treatment in real life.